Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China

Xiang Xiao, Shuming Ji, Tao Zheng, Tianzhu Wang, Dapeng Jiang, Fang Liu · 2024

Read Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China by Xiang Xiao, Shuming Ji, Tao Zheng, Tianzhu Wang, Dapeng Jiang, Fang Liu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11649429.txt.

Description

Xiang Xiao and co-authors compare kidney outcomes for a newer class of diabetes drug in real Chinese hospital records, in a 2024 paper. The drugs, called SGLT2 inhibitors, lower blood sugar by letting it spill into urine. Trials abroad suggest they also protect the kidneys, but day-to-day evidence from mainland China was scarce. The team studied patients who had both type 2 diabetes and chronic kidney disease.

Records from West China Hospital covered 944 such patients. Of them, 605 started the newer drugs, and 339 took older glucose-lowering medicines. Follow-up ran for a median of about seventeen to twenty-one months. The newer-drug group lost kidney function more slowly, with the yearly slide in their filtration rate clearly smaller. The study adds real-world weight to using these drugs when diabetes and kidney disease arrive together.

Catalog record

CREATORXiang Xiao, Shuming Ji, Tao Zheng, Tianzhu Wang, Dapeng Jiang, Fang Liu
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11649429

Browse the full library · About the Tower of Babel